NCT01454349 - Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

August 31, 2013

Conditions

Benign Prostatic Hyperplasia

Interventions

DRUG

PRX302

Single intraprostatic injection with an ascending dose per cohort of 0.75, 1.5, 3.0, and 6.0 µg/mL

DRUG

Placebo

Single intraprostatic injection of matching placebo

Trial Locations (15)

10016

University Urology Associates, New York

11530

Accumed Research Associates, Garden City

12601

Premier Medical Group of the Hudson Valley, Poughkeepsie

19004

Urologic Consultants of SE Pennsylvania, Bala-Cynwyd

29572

Carolina Urologic Research Center, Myrtle Beach

33180

South Florida Medical Research, Aventura

45212

TriState Urological Services, Cincinnatti

50266

The Iowa Clinic, West Des Moines

60611

Northwestern University, Chicago

75010

Research Across America, Carrollton

75390

UT Southwestern Medical Center, Dallas

80045

University of Colorado Denver, Aurora

90806

Atlantic Urology Medical Group, Long Beach

92653

South Orange County Medical Research Center, Laguna Hills

92660

California Professional Research, Newport Beach

All Listed Sponsors

lead

Sophiris Bio Corp

INDUSTRY